Tech Company Financing Transactions
Oculis Funding Round
Oculis closed a $125 million funding round on 8/5/2025. Backers included BlackRock.
Transaction Overview
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Bahnhofstrasse 20
Zug, 6300
Switzerland
Zug, 6300
Switzerland
Phone
Website
Email Address
Not Recorded
Overview
Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. We are driven by patients suffering from eye diseases to develop transformative innovations that have the potential to address remaining unmet medical needs in ophthalmology and enhance patients' everyday lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Riad Sherif
Browse more venture capital transactions:
Prev: 8/5/2025: Grasshopper venture capital transaction
Next: 8/5/2025: Daedalean venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs